These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 34851425)

  • 41. Does intranasal dexmedetomidine provide adequate plasma concentrations for sedation in children: a pharmacokinetic study.
    Miller JW; Balyan R; Dong M; Mahmoud M; Lam JE; Pratap JN; Paquin JR; Li BL; Spaeth JP; Vinks A; Loepke AW
    Br J Anaesth; 2018 May; 120(5):1056-1065. PubMed ID: 29661383
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain.
    Xu XS; Smit JW; Lin R; Stuyckens K; Terlinden R; Nandy P
    Clin Pharmacokinet; 2010 Oct; 49(10):671-82. PubMed ID: 20818833
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pharmacokinetic evidence for suboptimal treatment of adrenal insufficiency with currently available hydrocortisone tablets.
    Simon N; Castinetti F; Ouliac F; Lesavre N; Brue T; Oliver C
    Clin Pharmacokinet; 2010 Jul; 49(7):455-63. PubMed ID: 20528006
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pharmacokinetics of computer-controlled alfentanil administration in children undergoing cardiac surgery.
    Fiset P; Mathers L; Engstrom R; Fitzgerald D; Brand SC; Hsu F; Shafer SL
    Anesthesiology; 1995 Nov; 83(5):944-55. PubMed ID: 7486179
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 mg-10 mg) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects.
    Retlich S; Duval V; Ring A; Staab A; Hüttner S; Jungnik A; Jaehde U; Dugi KA; Graefe-Mody U
    Clin Pharmacokinet; 2010 Dec; 49(12):829-40. PubMed ID: 21053992
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Population pharmacokinetics of dexmedetomidine in critically ill patients.
    Välitalo PA; Ahtola-Sätilä T; Wighton A; Sarapohja T; Pohjanjousi P; Garratt C
    Clin Drug Investig; 2013 Aug; 33(8):579-87. PubMed ID: 23839483
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and pharmacodynamics of propofol/alfentanil infusions for sedation in ICU patients.
    Frenkel C; Schuttler J; Ihmsen H; Heye H; Rommelsheim K
    Intensive Care Med; 1995 Dec; 21(12):981-8. PubMed ID: 8750122
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose Escalation Pharmacokinetic Study of Intranasal Atomized Dexmedetomidine in Pediatric Patients With Congenital Heart Disease.
    Grogan K; Thibault C; Moorthy G; Prodell J; Nicolson SC; Zuppa A
    Anesth Analg; 2023 Jan; 136(1):152-162. PubMed ID: 35446797
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Population pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor--in patients undergoing major orthopaedic surgery.
    Mueck W; Eriksson BI; Bauer KA; Borris L; Dahl OE; Fisher WD; Gent M; Haas S; Huisman MV; Kakkar AK; Kälebo P; Kwong LM; Misselwitz F; Turpie AG
    Clin Pharmacokinet; 2008; 47(3):203-16. PubMed ID: 18307374
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
    Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
    J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
    Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
    Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dose rationale and pharmacokinetics of dexmedetomidine in mechanically ventilated new-borns: impact of design optimisation.
    van Dijkman SC; De Cock PAJG; Smets K; Decaluwe W; Smits A; Allegaert K; Vande Walle J; De Paepe P; Della Pasqua O
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1393-1404. PubMed ID: 31312867
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The pharmacokinetics of dexmedetomidine during long-term infusion in critically ill pediatric patients. A Bayesian approach with informative priors.
    Wiczling P; Bartkowska-Śniatkowska A; Szerkus O; Siluk D; Rosada-Kurasińska J; Warzybok J; Borsuk A; Kaliszan R; Grześkowiak E; Bienert A
    J Pharmacokinet Pharmacodyn; 2016 Jun; 43(3):315-24. PubMed ID: 27221375
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
    Joerger M; Kraff S; Huitema AD; Feiss G; Moritz B; Schellens JH; Beijnen JH; Jaehde U
    Clin Pharmacokinet; 2012 Sep; 51(9):607-17. PubMed ID: 22804749
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dexmedetomidine disposition in children: a population analysis.
    Potts AL; Warman GR; Anderson BJ
    Paediatr Anaesth; 2008 Aug; 18(8):722-30. PubMed ID: 18613931
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias.
    Periclou AP; Avramis VI
    Cancer Chemother Pharmacol; 1996; 39(1-2):42-50. PubMed ID: 8995498
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prospective, double-blind, randomized, placebo-controlled study of dexmedetomidine as an adjunct to epidural analgesia after thoracic surgery.
    Wahlander S; Frumento RJ; Wagener G; Saldana-Ferretti B; Joshi RR; Playford HR; Sladen RN
    J Cardiothorac Vasc Anesth; 2005 Oct; 19(5):630-5. PubMed ID: 16202898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A population pharmacokinetic/pharmacodynamic analysis of regadenoson, an adenosine A2A-receptor agonist, in healthy male volunteers.
    Gordi T; Frohna P; Sun HL; Wolff A; Belardinelli L; Lieu H
    Clin Pharmacokinet; 2006; 45(12):1201-12. PubMed ID: 17112296
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using Real-World Data to Externally Evaluate Population Pharmacokinetic Models of Dexmedetomidine in Children and Infants.
    McCann S; Helfer VE; Balevic SJ; Hornik CD; Goldstein SL; Autmizguine J; Meyer M; Al-Uzri A; Anderson SG; Payne EH; Turdalieva S; Gonzalez D;
    J Clin Pharmacol; 2024 Aug; 64(8):963-974. PubMed ID: 38545761
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Eculizumab dose tapering should take into account the nonlinearity of its pharmacokinetics.
    Le Tilly O; Gatault P; Semlali S; Sberro-Soussan R; Passot C; Bertrand D; Desvignes C; Caillard S; Paintaud G; Halimi JM; Ternant D
    Br J Clin Pharmacol; 2024 May; 90(5):1312-1321. PubMed ID: 38373846
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.